𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors

✍ Scribed by Kun Zhu; Danni Qu; Takanori Sakamoto; Ichio Fukasawa; Masatoshi Hayashi; Noriyuki Inaba

Publisher
Springer
Year
2007
Tongue
English
Weight
322 KB
Volume
277
Category
Article
ISSN
0003-9128

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Histone deacetylase inhibitors suppress
Histone deacetylase inhibitors suppress telomerase reverse transcriptase mrna expression in prostate cancer cells
✍ Mitsuhiro Suenaga; Hiroshi Soda; Mikio Oka; Akihiko Yamaguchi; Katsumi Nakatomi; πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 398 KB

## Abstract Telomerase activity is involved in cellular immortality. We have recently demonstrated that telomerase activity is closely associated with cell proliferation in prostate cancers. Telomerase is composed primarily of the catalytic subunit (hTERT) and the RNA template (hTERC), and __hTERT_

Reduction of telomerase activity in huma
Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor
✍ Mitsuyasu Nakamura; Hidetsugu Saito; Hirotoshi Ebinuma; Kanji Wakabayashi; Yoshi πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 322 KB

## Abstract The presence of telomerase has been demonstrated recently in many different malignancies. Several reports documented that in human hepatocellular carcinoma, the level of telomerase activity parallels its differentiation stage. In the present study, the effect of the differentiation‐indu

Histone deacetylase inhibitors suppress
Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells
✍ William Fazzone; Peter M. Wilson; Melissa J. LaBonte; Heinz-Josef Lenz; Robert D πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 French βš– 532 KB

## Abstract Despite recent therapeutic advances, the response rates to chemotherapy for patients with metastatic colon cancer remain at ∼50% with the fluoropyrimidine, 5‐fluorouracil (5‐FU), continuing to serve as the foundation chemotherapeutic agent for the treatment of this disease. Previous stu